Skip to main content
COMMAND CLIENT / DEMO ENVIRONMENT • SAMPLE SIGNALS ONLY • NO LIVE API CONNECTIONS
AimwellBio Intelligence Platform
CLIENT Trial Signal Shield Command Growth Enterprise Alumni Partner FHIN Observer Contributor Researcher Institutional Community ↗
Intelligence Dashboard
Command Tier — Last refreshed: Apr 19, 2026 — 09:14 UTC
Positions Monitored
38
across 9 indications
Signals / 24h
142
9 sources, 4 verticals
Adversarial Agents
3
active validations running
Network Depth
2,140
verified contributors
Decision Integrity
0.91
avg confidence, 7-day
Enterprise Configuration
  • Dedicated account setup Your dedicated AimwellBio account manager will reach out within 48h.
  • Custom signal configuration Tailored to your therapeutic focus areas and competitive landscape.
  • API access credentials — scheduled for member release API endpoint is in private beta; credentials are provisioned to your admin email after approval during onboarding.
  • Team seat provisioning Share access with your team — contact your account manager to add seats.
SIGNAL STREAM · SAMPLE PREVIEW
142 / 24h
09:14 FDA Commissioner memo — expedited pathway reform, metabolic disease 0.97 08:51 Lilly 8-K — $3.2B accelerated share repurchase 0.99 08:27 AZ — AZD5004 Phase 3 obesity study registered (NCT06813841) 0.93 07:48 EMA PRAC GLP-1 thyroid C-cell tumor safety review opened 0.96 07:12 NEJM — SURPASS-CVOT renal sub-analysis, 28% eGFR decline reduction 0.92 06:34 Amgen MariTide OASIS-1 enrollment closed, 1,840 patients 0.95 05:58 Roche/Zealand petrelintide Phase 2b interim — 47-pt weight loss 0.84 05:21 CMS prior auth AI rule — 60-day comment window opens 0.88 04:47 PMDA — oral semaglutide bioavailability review request filed 0.82 04:09 Hanmi-AZ triple agonist licensing chatter, $2.4B framework 0.87 03:32 EMA AI/ML qualification opinion draft — ICH E9(R1) alignment 0.71 02:58 Reuters — Novo CV outcomes data strengthens payer access 0.79
ADVERSARIAL VALIDATION · ACTIVE
3 jobs
Lilly SURPASS-CVOT cross-validation
PROCEED 4 DELAY 2 KILL 1
Consensus 71% · 14 source docs
Novo SELECT CV label review
PROCEED 5 DELAY 1 KILL 0
Consensus 86% · FDA label cross-ref complete
EMA semaglutide thyroid review
PROCEED 1 DELAY 4 KILL 2
Consensus 57% DELAY · 9 source docs
Cortex AI — Biopharma Intelligence Engine
Command: Unlimited
RS
You
What are the FDA fast-track pathways for GLP-1 drugs?
CX
Cortex
FDA offers three primary expedited pathways for GLP-1 assets: Fast Track Designation (FTD) — requestable at any stage, enables rolling NDA/BLA review, FDA responds within 60 days; Breakthrough Therapy Designation (BTD) — requires substantial improvement on a clinically significant endpoint, has driven semaglutide CV label and tirzepatide obesity approval; and Accelerated Approval (AA) — requires a surrogate endpoint reasonably likely to predict benefit, typically paired with a confirmatory trial requirement. For Command-tier members, I've cross-referenced your 18 active dossiers: 4 assets in your pipeline may qualify for FTD based on their current Phase 2 endpoint selection. Shall I generate a pathway eligibility matrix? Queue SCOUT analysis
RS
You
Which competitors have Phase 3 data?
CX
Cortex
Active GLP-1 Phase 3 landscape (Q1 2026): Novo Nordisk — semaglutide SELECT (CV, approved), STEP 9 (NASH, 76-wk data expected Q3 2026); Eli Lilly — tirzepatide SURMOUNT-4 extension data, SURPASS-CVOT final readout Q2 2026; Amgen — maridebart cafraglutide OASIS-1 enrollment complete (topline ~Q1 2027). Validation Layer has flagged 2 SEC filings from Lilly and Novo from the past 7 days — review validation queue for risk-adjusted competitive positioning.
Try:
Signal Feed
142 Active
FDA Regulatory
FDA Commissioner Memo: Expedited Pathway Reform for Metabolic Disease Targets
Apr 19, 2026 Confidence: 97% HIGH
SEC Financial
Eli Lilly 8-K: Board Approves $3.2B Accelerated Share Repurchase — Pipeline Confidence Signal
Apr 18, 2026 Confidence: 99% MEDIUM
ClinicalTrials Clinical
AstraZeneca Registers GLP-1/GIP Dual Agonist AZD5004 Phase 3 Obesity Study (NCT06813841)
Apr 17, 2026 Confidence: 93% HIGH
PubMed Scientific
NEJM: Renal Outcomes Sub-Analysis of SURPASS-CVOT Demonstrates 28% eGFR Decline Reduction
Apr 15, 2026 Confidence: 92% MEDIUM
SCOUT — Automated Intelligence Runs
4 This Month
GLP-1 competitive landscape — full pipeline scan
Started Apr 19, 09:02 UTC • Est. 14 min remaining
Running
FDA advisory committee calendar Q2-Q3 2026
Queued • Starts after active run completes
Queued
Tirzepatide NASH indication signal sweep
Completed Apr 18, 16:33 UTC • 47 signals found
Complete
EMA safety surveillance — GLP-1 class review
Completed Apr 17, 11:14 UTC • 23 signals found
Complete
Validation Layer — Active Jobs
2 Active
Lilly SURPASS-CVOT Data Cross-Validation
78%
Validating against 14 source documents • 3 conflicts flagged
Novo Nordisk SELECT CV Label Review
41%
Cross-referencing FDA label vs. trial publications • 1 conflict flagged
Recently Completed
Amgen MariTide CMC file validation — Passed
AZD5004 Phase 3 protocol validation — Passed
Public Profile Preview — what others see
View Public Profile ↓
MORNING BRIEFINGS · 3 NEW
2026-05-24 · 06:00 UTC
GLP-1 payer access — CV outcomes data shifts the price floor
Three commercial payers signaled tier-3 placement reconsideration following SURPASS-CVOT renal sub-analysis. Pricing pressure window narrows; tirzepatide gains positioning leverage versus semaglutide. 14 source citations.
2026-05-23 · 06:00 UTC
EMA PRAC thyroid C-cell tumor review — what's actually at stake
PRAC opened formal review with rapporteur appointment May 22. Historical base rate of label-change outcomes for similar class-wide signals: 38%. Adversarial validation DELAY consensus 57%.
2026-05-22 · 06:00 UTC
CMS prior auth AI rule — what the 60-day window means for biopharma
Comment window closes July 21. Three trade associations have already filed; PhRMA position memo expected by month-end. Cross-references ICH E9(R1) and FDA AI/ML guidance from Q1.
COMMAND → ENTERPRISE

What does intelligence look like when it scales to the whole portfolio?

Command runs the terminal. Enterprise runs the institution. Custom adversarial agents trained on your pipeline assumptions, dedicated SCOUT capacity, portfolio-wide validation throughput, and an analyst desk that opens at your hours. Before you upgrade, see what your team actually uses Command for — we will build the Enterprise spec from your last 90 days of activity, not from a brochure.

Custom adversarial agents Dedicated SCOUT capacity API access (member release scheduled) & bulk dossier exports Portfolio-impact heatmap Analyst desk & SLA
Talk to Sarah about Enterprise →
Confidence-scored · Source-traced · Adversarially validated
What you have on Command
Your plan
Active now
AIMN:VERDICT generation — source-traced answers on demand.
Vault read & write — your organization’s saved intelligence.
Atlas access — the indexed source graph.
In activation
Signal feed, alerts, watchlist, dossier, competitor monitoring, and simulation are included in Command and are being switched on during onboarding. Anything labeled Sample on this page is illustrative until your data is activated.
Your next best step
Get value today
Your verdict engine and vault are active right now. While monitoring and simulation finish activating, the fastest way to put Command to work today is to run a real decision through AIMN:VERDICT and save the verdict to your vault for the team to act on.
Run a verdict Set up your watchlist for activation
What your Command membership keeps doing for you
Your value
While your membership is active, your verdict engine, your vault, and Atlas access stay on, and everything your organization saves stays yours to return to. Signal feed, alerts, watchlist, dossier, competitor monitoring, and simulation keep moving toward activation. You can review your plan or talk to us any time.
Manage billing & subscription →

Your Command membership — status & next step

Where your plan standsCommand · active
Verdict engine, organization vault & Atlas accessActive now
Dossier, competitor monitoring & simulationIn activation
Organization-wide configurationRequires onboarding
What's in the corpus behind your programsCurated · scheduled
9,270
signals
383
companies
9
areas
4
source types

Dataset-level totals across the curated corpus — PubMed/NCBI, U.S. FDA, ClinicalTrials.gov, and SEC EDGAR. Counts reflect the most recent scheduled compile — a curated snapshot, not a streaming source.

Your next best move

Request your Command configuration so we can scope organization-wide access, the indication areas your programs cover, and your point of contact. That is what activates Command across your team rather than a single seat.

Request configuration → Review a dossier sample →

Command is the top tier — there is no higher plan to upgrade to. Your relationship is sales-assisted; reach your point of contact any time to adjust scope.

If you cancel

Your verdict engine, organization vault, and Atlas access switch off, and dossier, competitor monitoring, and simulation stop moving toward activation. Everything your organization has saved stays exportable while your plan is active — export what you need to keep before the period ends.

Manage billing & subscription →
Refer a colleague

Share a dossier sample with a peer running an adjacent program — it is the clearest demonstration of the work AimwellBio prepares at the Command level.

AimwellBio provides decision-support intelligence. It is not medical, legal, regulatory, or investment advice. Sources and outputs should be reviewed by qualified professionals before action.